These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35855239)

  • 21. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS).
    Bireley JD; Morren JA
    Expert Opin Investig Drugs; 2023; 32(8):677-683. PubMed ID: 37642362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultrasound-enhanced brain delivery of edaravone provides additive amelioration on disease progression in an ALS mouse model.
    Shen Y; Zhang J; Xu Y; Sun S; Chen K; Chen S; Yang X; Chen X
    Brain Stimul; 2023; 16(2):628-641. PubMed ID: 36931463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of Therapeutic Response of Edaravone and Riluzole Combination Therapy in Amyotrophic Lateral Sclerosis Patients.
    Samadhiya S; Sardana V; Bhushan B; Maheshwari D; Goyal R; Pankaj
    Ann Indian Acad Neurol; 2022; 25(4):692-697. PubMed ID: 36211189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective?
    Bassani D; Pavan M; Federico S; Spalluto G; Sturlese M; Moro S
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral Edaravone - Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis.
    Pattee GL; Genge A; Couratier P; Lunetta C; Sobue G; Aoki M; Yoshino H; Jackson CE; Wymer J; Salah A; Nelson S
    Expert Rev Neurother; 2023; 23(10):859-866. PubMed ID: 37646130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug discovery and amyotrophic lateral sclerosis: Emerging challenges and therapeutic opportunities.
    Soares P; Silva C; Chavarria D; Silva FSG; Oliveira PJ; Borges F
    Ageing Res Rev; 2023 Jan; 83():101790. PubMed ID: 36402404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022.
    Jiang J; Wang Y; Deng M
    Front Pharmacol; 2022; 13():1054006. PubMed ID: 36518658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amyotrophic lateral sclerosis: current understanding.
    Charles T; Swash M
    J Neurosci Nurs; 2001 Oct; 33(5):245-53. PubMed ID: 11668883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breaking barriers with tofersen: Enhancing therapeutic opportunities in amyotrophic lateral sclerosis.
    Saini A; Chawla PA
    Eur J Neurol; 2024 Feb; 31(2):e16140. PubMed ID: 37975798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents.
    Johnson SA; Fang T; De Marchi F; Neel D; Van Weehaeghe D; Berry JD; Paganoni S
    Drugs; 2022 Sep; 82(13):1367-1388. PubMed ID: 36121612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Edaravone Oral Suspension: A Neuroprotective Agent to Treat Amyotrophic Lateral Sclerosis.
    Singh P; Belliveau P; Towle J; Neculau AE; Dima L
    Am J Ther; 2024 May-Jun 01; 31(3):e258-e267. PubMed ID: 38691665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System.
    Vu M; Tortorice K; Zacher J; Dong D; Hur K; Zhang R; Good CB; Glassman PA; Cunningham FE
    JAMA Netw Open; 2020 Oct; 3(10):e2014645. PubMed ID: 33017028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis.
    Sever B; Ciftci H; DeMirci H; Sever H; Ocak F; Yulug B; Tateishi H; Tateishi T; Otsuka M; Fujita M; Başak AN
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Edaravone counteracts redox and metabolic disruptions in an emerging zebrafish model of sporadic ALS.
    Oliveira NAS; Pinho BR; Pinto J; Guedes de Pinho P; Oliveira JMA
    Free Radic Biol Med; 2024 May; 217():126-140. PubMed ID: 38531462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study protocol of RESCUE-ALS: A Phase 2,
    Vucic S; Kiernan MC; Menon P; Huynh W; Rynders A; Ho KS; Glanzman R; Hotchkin MT
    BMJ Open; 2021 Jan; 11(1):e041479. PubMed ID: 33431491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complementary and alternative medicine for treating amyotrophic lateral sclerosis: A narrative review.
    Cai M; Yang EJ
    Integr Med Res; 2019 Dec; 8(4):234-239. PubMed ID: 31692669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Adamantane-Containing Edaravone Conjugates as Potential Neuroprotective Agents for ALS Treatments.
    Lapshina MA; Shevtsova EF; Grigoriev VV; Aksinenko AY; Ustyugov AA; Steinberg DA; Maleev GV; Dubrovskaya ES; Goreva TV; Epishina TA; Zamoyski VL; Makhaeva GF; Fisenko VP; Veselov IM; Vinogradova DV; Bachurin SO
    Molecules; 2023 Nov; 28(22):. PubMed ID: 38005288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis.
    Noto Y; Shibuya K; Vucic S; Kiernan MC
    Expert Rev Neurother; 2016 Oct; 16(10):1147-54. PubMed ID: 27314534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical trial landscape in amyotrophic lateral sclerosis-Past, present, and future.
    Wobst HJ; Mack KL; Brown DG; Brandon NJ; Shorter J
    Med Res Rev; 2020 Jul; 40(4):1352-1384. PubMed ID: 32043626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.